Lynda Chin, M.D. joined the University of Texas System as associate vice chancellor for health transformation and chief innovation officer for health affairs in 2015.
Chin trained as a physician at Albert Einstein College of Medicine in 1993, and is a board-certified dermatologist. She conducted her clinical and scientific training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine where she was appointed Chief Resident of Dermatology. Previous to joining the University of Texas MD Anderson Cancer Center in 2011, she was a member of the Dana-Farber Cancer Institute and Harvard Medical School communities. Chin was one of the founding faculty members and the Scientific Director of the Belfer Institute for Applied Cancer Science.
Chin was also the founding chair of the Department of Genomic Medicine at MD Anderson. She served as the scientific director of the Institute for Applied Cancer Science, which merges the best attributes of academia and industry to enable science-driven drug discovery. Chin is a leader in translational genomic medicine and her research program spans the fields of transcription, telomere biology, mouse models of human cancer, cancer genomics, and personalized cancer medicine. She is also at the forefront of comparative oncogenomics of mouse and human cancers and its integration with functional genomics to identify novel cancer genes and therapeutic targets.
Chin is also actively involved in The Cancer Genome Atlas, where she holds multiple leadership roles. She is also a member of the Scientific Steering Committee of the International Cancer Genome Consortium. Chin was elected a member of the Institute of Medicine in 2012. She co-founded AVEO Pharmaceuticals in 2002, which emphasizes cancer biology and genetics to identify new cancer targets with tumor maintenance roles. More recently, Chin also founded Metamark Genetics, a diagnostic company that develops function-based prognostic determinants to guide the customized management of early-stage cancer patients with melanoma or prostate cancer. Chin has three young children, ages 11, 10 and 8.
June 25, 2019
© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.